Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20864290 | 1.00 | USP7 (0.80) | USP7USP19 | |
| SCHEMBL20864315 | 1.00 | USP7 (0.80) | USP7USP19 | |
| SCHEMBL17937970 | 0.97 | USP7 (0.85) | USP7USP19 | |
| SCHEMBL20864341 | 0.92 | USP7 (0.69) | USP7USP19 | |
| SCHEMBL26036532 | 0.90 | USP7 (0.82) | USP7USP19 | |
| SCHEMBL26036538 | 0.90 | USP7 (0.82) | USP7USP19 | |
| SCHEMBL20864304 | 0.90 | USP7 (0.72) | USP7USP19 | |
| SCHEMBL20864524 | 0.90 | USP7 (0.69) | USP7USP19 | |
| SCHEMBL20864772 | 0.90 | USP7 (0.71) | USP7USP19 | |
| SCHEMBL20864523 | 0.90 | USP7 (0.71) | USP7USP19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546150-B2 | Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 | HYBRIGENICS SA (FR) | 2017-01-17 | — | — | US | claimed |
| EP-2751092-B1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2016-07-27 | — | — | EP | claimed |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | HYBRIGENICS SA (FR) | 2014-12-18 | — | — | US | claimed |
| EP-2751092-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Hybrigenics S.A. (FR) | 2014-07-09 | — | — | EP | claimed |
| WO-2013030218-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2013-03-07 | — | — | WO | claimed |
| US-20230265070-A1 | NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265070-A1 | NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20220125760-A1 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) | 2022-04-28 | — | — | US | disclosed |
| EP-3923987-A1 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2021-12-22 | — | — | EP | disclosed |
| US-20200347031-A1 | NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2020-11-05 | — | — | US | disclosed |
| WO-2020165315-A1 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-08-20 | — | — | WO | disclosed |
| WO-2019067503-A1 | NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| EP-2751092-B1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2016-07-27 | — | — | EP | disclosed |
| EP-2751092-B1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2016-07-27 | — | — | EP | disclosed |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | HYBRIGENICS SA (FR) | 2014-12-18 | — | — | US | disclosed |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | HYBRIGENICS SA (FR) | 2014-12-18 | — | — | US | disclosed |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | HYBRIGENICS SA (FR) | 2014-12-18 | — | — | US | disclosed |
| EP-2751092-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Hybrigenics S.A. (FR) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013030218-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030218-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265070-A1 | NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA | USP7, USP1, USP3 | USP7 1/4885USP19 8/4885 |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | USP7, UBA7, SENP7 | USP7 1/4885USP19 20/4885 |
| US-20200347031-A1 | NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA | USP7, USP1, USP3 | USP7 1/4885USP19 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.